Buscar
Mostrando ítems 51-60 de 592
Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia
(FUTURE MEDICINE LTD, 2011)
Aim: A cost effectiveness analysis was performed to assess the potential value of companion diagnostics in supporting treatment decisions for dasatinib and nilotinib in chronic myeloid leukemia. Materials & methods: A ...
Closo-Carboranyl- and Metallacarboranyl [1,2,3]triazolyl-Decorated Lapatinib-Scaffold for Cancer Therapy Combining Tyrosine Kinase Inhibition and Boron Neutron Capture Therapy
(MPDI, 2020-06)
One of the driving forces of carcinogenesis in humans is the aberrant activation of receptors; consequently, one of the most promising mechanisms for cancer treatment is receptor inhibition by chemotherapy. Although a ...
Angiotensin-converting enzyme inhibitor increases insulin-induced pp185 phosphorylation in liver and muscle of obese rats
(Academic Press AustMarrickvilleAustralia, 1998)
Cediranib: a VEGF receptor tyrosine kinase inhibitor
(FUTURE MEDICINE LTDLONDON, 2012)
Cediranib is a potent inhibitor of the VEGF family receptor tyrosine kinases, and a new agent in cancer treatment. The drug has shown promising activity in a variety of solid malignancies, in preclinical models and in ...
Functional Diversity of the Schistosoma mansoni Tyrosine Kinases
(Hindawi Publishing, 2014)
Direct inhibition of the hexose transporter glut1 by tyrosine kinase inhibitorsBIOCHEMISTRY (EASTON)BIOCHEMISTRY (EASTON)
(AMERICAN CHEMICAL SOCIETY, 2017)
Non-small cell lung cancer transdifferentiation into small cell lung cancer: A case series
(2018)
Transdifferentiation from non-small cell lung cancer (NSCLC) to small cell lung cancer (SCLC) has been reported mostly in adenocarcinomas and has been described as a cause of acquired tyrosine kinase inhibitor (TKI) ...